• Galmed Pharmaceuticals will rebrand as Eocene, shifting its Nasdaq Capital Market ticker to EOCN effective Sept. 10, 2026.
• Ordinary shares will keep trading on Nasdaq without interruption under the new symbol.
• Nasdaq minimum bid price compliance was regained, supporting the continued listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041872), on September 09, 2026, and is solely responsible for the information contained therein.